Trials / Recruiting
RecruitingNCT07534033
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Zhujiang Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include: Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment? Participants will: Take LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions
Conditions
- NSCLC Diagnosed by Histology or Cytology
- A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection
- Overall Lung Function is Adequate for the Planned Lung Resection
- AJCC is Classified as IB-IIIC
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Probiotics combined with neoadjuvant chemoimmunotherapy | This clinical study aims to enhance efficacy by using functional probiotics selected from a Chinese food-grade probiotic library in combination with neoadjuvant chemoimmunotherapy. |
Timeline
- Start date
- 2025-12-06
- Primary completion
- 2026-12-23
- Completion
- 2027-12-23
- First posted
- 2026-04-16
- Last updated
- 2026-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07534033. Inclusion in this directory is not an endorsement.